MorphoSys AG Release: AbD Serotec Receives Large Research Antibody Order From Proteomics Specialist Proteomika

MARTINSRIED, Germany, March 5, 2008 (PRIME NEWSWIRE) -- MorphoSys AG (FSE:MOR) (Prime Standard Segment:TecDAX) today announced that its AbD Serotec business unit has received a multiple research antibody order from Proteomika SL, a Spanish biotechnology company specializing in biomarker discovery. Proteomika has ordered novel, HuCAL-based, research antibodies against a broad range of target molecules in addition to the production of antigen material at AbD Serotec. AbD Serotec will apply MorphoSys's HuCAL GOLD antibody technology and the proprietary Antigen Expression System AgX(tm). The order ranks Proteomika among the largest customers for custom monoclonals services provided by AbD Serotec. Financial details of the agreement were not disclosed.